Lived experiences of patients receiving maintenance therapy with PARP inhibitors for advanced ovarian cancer

Abstract

Objective Advanced ovarian cancer is often diagnosed at stages IIIB-IV, with frequent recurrence and poor prognosis despite standard treatment. Poly(ADP-ribose) polymerase (PARP) inhibitors are available as maintenance therapies; nonetheless, evidence on patient experiences remains limited. This study clarified patient experiences during maintenance therapy with PARP inhibitors and identified nursing support implications.

Methods We used a descriptive qualitative design. Three women with advanced ovarian cancer (40s-70s; FIGO stage IIIB-IIIC; two with recurrence) attending an outpatient clinic were recruited. Semi-structured interviews were conducted up to five times within 6 months after therapy initiation (total, 531 min), and medical records were reviewed. Transcripts were analyzed using the KJ method.

Results Seven categories were identified. Patients described PARP inhibitors as “a talisman-like treatment” that provided reassurance and enabled them to navigate daily life despite concerns about heredity and financial burden; they valued “the support of family, colleagues, and healthcare providers” and wished “to live by trusting in PARP inhibitors even under uncertainty.” They reported “symptom observation and daily management” as self-care strategies and expressed “fear of cancer and harsh treatments,” “conflicts in regaining self-identity,” and a strong need “for a place to consult about symptoms, costs, and continuation of therapy.”

Conclusions Patients balanced reassurance and uncertainty, supported by treatment efficacy and social relationships, but challenged by fear, financial strain, and identity loss. Nurses should assess these experiences and provide individualized consultations addressing symptoms, economic concerns, and genetic issues. Early, continuous consultation and strengthened multidisciplinary collaboration are essential to sustain treatment and improve quality of life.

Keywords

Gynecological tumors / Ovarian cancer / PARP inhibitors / Quality of life

References

[1] Tokunaga H, Mikami M, Nagase S, et al. The 2020 Japan Society of Gynecologic Oncology guidelines for the treatment of ovarian cancer, fallopian tube cancer, and primary peritoneal cancer. J Gynecol Oncol. 2021; 32(2): e49. PMid:33650343 https://doi.org/10.3802/jgo.2021.32.e49

[2] Harter P, Sehouli J, Lorusso D, et al. A randomized trial of lymphadenectomy in patients with advanced ovarian neoplasms. N Engl J Med. 2019; 380(9): 822-32. PMid:30811909 https://doi.org/10.1056/NEJMoa1808424

[3] Pujade-Lauraine E, Ledermann JA, Selle F, et al. Olaparib tablets as maintenance therapy in patients with platinum-sensitive, relapsed ovarian cancer and a BRCA1/2 mutation (SOLO2/ENGOTOv21): a double-blind, randomised, placebo-controlled, phase 3 trial. Lancet Oncol. 2017; 18(9): 1274-84. PMid:28754483 https://doi.org/10.1016/S1470-2045(17)30469-2

[4] Guenther J, Stiles A, Champion JD. The lived experience of ovarian cancer: A phenomenological approach. J Am Acad Nurse Pract. 2012; 24(10): 595-603. PMid:23006018 https://doi.org/10.1111/j.1745-7599.2012.00732.x

[5] Qu A, Li N, Cong R, et al. A standardized psychological intervention procedure for ovarian cancer patients based on the Lazarus stress coping model. J Vis Exp. 2025; 224: e69100. https://doi.org/10.3791/69100

[6] Moskalewicz M, Popova Y, Wiertlewska-Bielarz J. Lived time in ovarian cancer - A qualitative phenomenological exploration. Eur J Oncol Nurs. 2022; 56: 102083. PMid:34998214 https://doi.org/10.1016/j.ejon.2021.102083

[7] Yamaura H. Introduction to qualitative integration method: ideas and procedures. Tokyo: Igaku-Shoin; 2012. Japanese.

[8] Okawa M, Aoki M, Arimori N. The experience of women diagnosed with hereditary breast and ovarian cancer (HBOC). Journal of the Japan Society of Cancer Nursing. 2018; 32: 98-108. https://doi.org/10.18906/jjscn.32_okawa_20180221

[9] Bakos AD, Hutson SP, Loud JT, et al. BRCA mutation-negative women from hereditary breast and ovarian cancer families: a qualitative study of the BRCA-negative experience. Health Expect. 2008; 11(3): 220-31. PMid:18816319 https://doi.org/10.1111/j.1369-7625.2008.00494.x

[10] Tsunoda A, Mochizuki R, Kanda K. The process by which patients with recurrent and/or progressive cancer who have recognized approaching death discover hope. Kitakanto Med J. 2016; 66(3): 201-9. https://doi.org/10.2974/kmj.66.201

[11] Mishel MH. Uncertainty in illness. Image J Nurs Sch. 1988 Winter; 20(4): 225-32. PMid:3203947 https://doi.org/10.1111/j.1547-5069.1988.tb00082.x

[12] Mishel MH. Reconceptualization of the uncertainty in illness theory. Image J Nurs Sch. 1990 Winter; 22(4): 256-62. PMid:2292449 https://doi.org/10.1111/j.1547-5069.1990.tb00225.x

[13] Yahiro Y, Nakai Y, Higashi A. A literature review of studies examining the psychological aspects of cancer patients receiving outpatient chemotherapy-references limited to only Japanese literature. Journal of the Japan Society for Nursing Research. 2012; 35(5): 129-36. https://doi.org/10.15065/jjsnr.20120821013

[14] Japanese Ministry of Health, Labour and Welfare. The 4th basic plan to promote cancer control programs. 2023. Available from: https://www.mhlw.go.jp/content/10901000/001091843.pdf (Accessed on 5 July 2025)

[15] Dancyger C, Smith JA, Jacobs C, et al. Comparing family members’ motivations and attitudes towards genetic testing for hereditary breast and ovarian cancer: a qualitative analysis. European Journal of Human Genetics. 2010; 18(12): 1289-95. PMid:20648056 https://doi.org/10.1038/ejhg.2010.114

[16] Hirschberg AM, Chan-Smutko G, Pirl WF. Psychiatric implications of cancer genetic testing. Cancer. 2015; 121(3): 341-60. PMid:25234846 https://doi.org/10.1002/cncr.28879

[17] Mella S, Muzzatti B, Dolcetti R, et al. Emotional impact on the results of BRCA1 and BRCA2 genetic test: an observational retrospective study. Hereditary Cancer in Clinical Practice. 2017; 15: 16. PMid:29026449 https://doi.org/10.1186/s13053-017-0077-6